Bharat Parenterals FY26 Consolidated Loss ₹27.3 Cr

Bharat Parenterals reported consolidated FY26 revenue of ₹345.4 Cr with a PAT loss of ₹27.3 Cr, driven by subsidiary Innoxel's pre-commercial phase.
Innoxel Lifesciences secured USFDA and EU-GMP approvals, signed 23 licensing deals worth ₹72.4 Cr, and targets EBITDA break-even in Q1 FY27.
Varenyam Healthcare delivered ₹58.4 Cr revenue with 31% YoY PCPM growth, while Varenyam Bio remains pre-revenue with ₹32.26 Cr CWIP.
Management guides FY27 growth across subsidiaries: Innoxel (35-45% revenue), Varenyam Healthcare (20-25%), and Varenyam Bio commissioning by Sep-2027.